SYNTARA LIMITED — Director's Dealing 2013

Dec 1, 2013

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PHARMAXIS LTD ABN 75 082 811 630

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the followingthe director for the purposes of section	information under listing rule 3.19A.2 and as agent for205G of the Corporations Act.
Name of Director	Gary Jonathan Phillips
Date of last notice	3 May 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.
Date of change	27 November 2013
No. of securities held prior to change	Ordinary shares: 60,000Options over ordinary shares: 1,195,000
Class	Options over ordinary shares
Number acquired	2,000,000
Number disposed	37,500
Value/ConsiderationNote: If consideration is non‐cash, provide details and estimatedvaluation	Acquired: Zero grant price and zero exerciseprice options grantedDisposed: Lapse of options granted 23 June2009
No. of securities held after change	Ordinary shares: 60,000Options over ordinary shares: 3,157,500

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Acquired: Grant of options under the Example: on‐market trade, off‐market trade, exercise of options, Pharmaxis Employee Option Plan following issue of securities under dividend reinvestment plan, participation in buy‐back shareholder approval Disposed: Lapse of options granted 23 June 2009 applicable to all Senior Managers. Lapsed 30 June 2013 and not advised earlier due to administrative oversight.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non‐cash, provide detailsand an estimated valuation
Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011